

The Manager
Company Announcements Office
ASX Limited

APAS® INDEPENDENCE DEMONSTRATION DEVICE READY AHEAD OF ECCMID CONFERENCE.

Adelaide, Australia, 30 March 2017: LBT Innovations (LBT) will today showcase the first APAS® Independence demonstration device in Melbourne before it is sent to the European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Vienna from April 22-25, 2017.

This event accompanies a recent announcement that APAS® has been included on the Australian Register of Therapeutic Goods as an in- vitro diagnostic device, and will see three presentations by key stake holders including:

- A business update by Brent Barnes, CEO and Managing Director of LBT
- The need for Automation in Microbiology by Lisa Brenton, Senior Scientist Microbiology, St Vincent's Hospital
- Experience in developing in- vitro diagnostics Stuart Elliott, CEO of Planet Innovation

LBT CEO and Managing Director Brent Barnes, says "it's with excitement to confirm the delivery of a functional APAS® Independence demonstration device in time for ECCMID as planned. Moreover I think it's helpful to give investors an opportunity to see the physical device along with hearing about the need for automation in microbiology from an experienced independent industry practitioner."

"APAS® is being developed under a Joint Venture called Clever Culture Systems, and we remain focused on demonstrating the technology at important global trade shows over the coming months and conduct commercialisation activities to support product sales in all key markets," said Mr Barnes.

APAS® is a breakthrough artificial intelligence technology and a global first for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. APAS® enables the faster diagnosis and reporting of infection and disease. The technology is at least three times more efficient than manual plate reading and meets the market need for helping with increased workloads, quality demands and decreasing budgets.

The investor briefing will be held at Planet Innovation, Ground Floor 436 Elgar Road Box Hill, Victoria at 4:30pm.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, US FDA-cleared APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.



LBT INNOVATIONS
ACN 107 670 673

CONTACTS

LBT Innovations	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Sarah Kemter Monsoon Communications Tel: +61 (0)3 9620 3333 M: +61 (0) 407 162 530 E: sarahk@monsoon.com.au